DEVELOPING ORAL LT3 THERAPY FOR HEART FAILURE (DOT3HF)

Recruiting

99 years or below

All

56 participants needed

1 Location

Brief description of study

Parallel, Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial The primary objective is to evaluate the safety of oral LT3 in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) The secondary objective is to evaluate the feasibility and preliminary efficacy outcomes of oral LT3 therapy in HFrEF and HFpEF.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: heart failure
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 833681

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).